Browse > Article

Synthesis of Decapeptide of L-Aspartic Acid and Benzyl-L-Aspartic Acid by Solid Phase Peptide Synthesis  

Yoo, Bong-K. (College of Pharmacy, Yeungnam University)
Jalil Miah, M.A. (College of Pharmacy, Chungbuk National University)
Lee, Eung-Seok (College of Pharmacy, Yeungnam University)
Han, Kun (College of Pharmacy, Chungbuk National University)
Publication Information
Archives of Pharmacal Research / v.28, no.7, 2005 , pp. 756-760 More about this Journal
Abstract
Polyene macrolide amphotericin B (AmB) is the drug of choice for the treatment of disseminated fungal infections. However, because of its pronounced side effects, the drug has limited applicability. There are few interesting reports, which state that co-administration of the drug with homo-peptide of polyaspartic acid reduces the side effects of the drug. In our present study, an approach has been made to systematically synthesize low molecular weight heteropeptides consisting of L-aspartic acid and its derivative. It was hypothesized that such heteropeptides will reduce the toxic side effects of the drug by facile hydrophobic binding between the polymer and the drug. We have employed the strategy of solid phase peptide synthesis (SPPS) to synthesize low molecular weight hetero-peptides by using L-aspartic acid and benzyl-L-aspartic acid to induce the hydrophobic binding between the peptide and the drug. In future, the proposed methodology can be employed to tailor other polypeptides substituted with benzyl groups to reduce the nephrotoxicity of AmB.
Keywords
Amphotericin B; Side effects; Decapeptides; L-Aspartic acid; Solid phase peptide synthesis;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Bodey, G. P., Anaissie, E. J., Elting, L. S., Estey, E., O'Brien, S., and Kantarjian, H., Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer, 73, 2099-2106 (1994)   DOI   PUBMED   ScienceOn
2 Borowski, E., Novel approaches in the rational design of antifungal agents of low toxicity. Farmaco, 55, 206-208 (2000)   DOI   ScienceOn
3 Branch, R. A., Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch. Intern. Med., 148, 2389-2394 (1988)   DOI   PUBMED   ScienceOn
4 Chernushevich, I. V., Loboda, A. V., and Thomson, B. A., An introduction to quadrupole.time-of-flight mass spectrometry. J. Mass Spectrom., 36, 849.865 (2001)   DOI   PUBMED   ScienceOn
5 Kishore, B. K., Kallay Z, Lambricht P, Laurent G, and Tulkens P. M., Mechanism of protection afforded by polyaspartic acid against gentamycin-induced phospholipidosis I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro. J. Pharmacol. Exp. Ther., 255, 867-874 (1990a)
6 Kishore, B. K., Lambricht, P., Laurent, G., Maldague, P., Wagner, R., and Tulkens, P. M., Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic, and poly-D-glutamic acids. J. Pharmacol. Exp. Ther., 255, 875-885 (1990b)
7 Saxena, S. and Ghosh, P. C., Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm. Res., 17, 1236-1242 (2000)   DOI   ScienceOn
8 Sheppard, R. C., Modern methods of solid-phase peptide synthesis. Science Tools, 33, 122-129 (1986)
9 Meyer, R. D., Young, L. S., Armstrong, D., and Yu, B., Aspergillosis complicating neoplastic disease. Am. J. Med., 54, 6-15 (1973)   DOI   ScienceOn
10 Whitelegge, J. P., Gundersen, C. B., and Faull, K. E., Electrosprayionization mass spectrometry of intact intrinsic membrane proteins. Protein Science, 7, 1423-1430 (1998)   DOI   ScienceOn
11 Brime, B., Molero, G.., Frutos P., and Frutos, G.., Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholateamphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. Eur. J. Pharm. Sci., 22, 451- 458 (2004)   DOI   ScienceOn
12 Kaloyanides G. J., Antibiotic-related nephrotoxicity. Nephrol. Dial. Transplant., 9 (suppl 4), 130-134 (1994)   PUBMED
13 Mann, M., Hendrickson, R. C., and Pandey, A., Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem., 70, 437-473 (2001)   DOI   ScienceOn
14 Berman, J. D., Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis., 24, 684-703 (1997)   DOI   ScienceOn
15 Mullen, A. B., Carter, K. C., and Baillie, A. J., Comparison of the efficacies of various formations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother., 41, 2089-2092 (1997)
16 Wiebe, V. J. and DeGregorio, M. W., Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis., 10, 1097-1101 (1988)   DOI
17 Brajtburg, J., Powderly, W. G., Kobayashi, G. S., and Madoff, G., Amphotericin B: delivery systems. Antimicrob. Agents Chemother., 34, 381-384 (1990)   DOI   PUBMED   ScienceOn
18 Townsend, R. W., Zutshi, A., and Bekersky, I., Biodistribution of 4-[(14) C] cholesterol-Ambisome following a single intravenous administration to rats. Drug Metb. Dispos., 29. 681- 685 (2001)   PUBMED
19 Warnock, D. W., Amphotericin B: an introduction. J. Antimicrob. Chemother., 28(Suppl. B), 27-38 (1991)   DOI
20 Miranda, L. P. and Alewood, P. F., Accelerated chemical synthesis of peptides and small proteins. Proc. Natl. Acad. Sci. U.S.A., 96, 1181-1186 (1999)   DOI
21 Carpino, L. A. and Han, G.. Y., 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem., 37, 3404-3409 (1972)   DOI
22 Merrifield, R. B., Solid phase peptide synthesis: the synthesis of a tetrapeptide. J. Am. Chem. Soc., 85, 2149-2154 (1963)   DOI